Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  H. Lundbeck A/S    LUN   DK0010287234

H. LUNDBECK A/S (LUN)

33
SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo H. Lundbeck A/S
Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases

H. Lundbeck A/S is engaged in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases.

It focuses in alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, stroke and symptomatic neurogenic orthostatic hypotension.

The company was founded by Hans Lundbeck on August 14, and is headquartered in Valby, Denmark.

Number of employees : 5 518 persons.
Sales per Businesses
20122013Delta
DKK (in Million)%DKK (in Million)%
Cipralex5,82739.4%5,93338.9% +1.79%
Ebixa2,80318.9%2,09613.7% -33.73%
Other Pharmaceuticals2,17414.7%1,83012% -18.8%
Azilect1,2248.3%1,3929.1% +12.07%
Xenazine1,1978.1%1,4209.3% +15.7%
Other626.004.2%1,4849.7% +57.82%
Lexapro575.003.9%---
Sabril376.002.5%530.003.5% +29.06%
Onfi--573.003.8%-
Sales per Regions
20122013Delta
DKK (in Million)%DKK (in Million)%
Rest of Europe7,68751.9%7,02846.1% -9.38%
Rest of the World3,76825.5%4,07526.7% +7.53%
United States2,67418.1%2,63517.3% -1.48%
Denmark47.000.3%36.000.2% -30.56%
Managers
NameAgeSinceTitle
Ulf Arne Wiinberg562008President & Chief Executive Officer
Sven Håkan Björklund MD, PhD582011Chairman
Anders Götzsche472007CFO & Executive VP-Information Technology
Anders Gersel Pedersen MD, PhD632000Executive Vice President-Research & Development
Thorleif Krarup622004Director
Jørn Møller Mayntzhusen, MBA482002Director & Senior Manager-Supply Optimisation
Christian Peter Dyvig, MBA502011Deputy Chairman
Mona Elisabeth Elster521994Director
Melanie Georgina Lee, PhD562012Independent Director
Lars Søren Rasmussen EMBA552013Director
Shareholders
NameShares%
Lundbeck Foundation 137,351,91869.9%
Wellington Management Co. LLP 3,148,2861.60%
Norges Bank Investment Management 2,570,2881.31%
OppenheimerFunds, Inc. 2,400,0001.22%
Templeton Global Advisors Ltd. 1,729,4970.88%
M&G Investment Management Ltd. 1,561,2550.80%
Franklin Templeton Investment Management Ltd. 1,365,1700.70%
Industriens Pensionsforsikring A/S 770,1020.39%
The Vanguard Group, Inc. 625,6040.32%
TIAA-CREF Investment Management LLC 614,3130.31%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
NOVARTIS AG
ROCHE HOLDING LTD..
PFIZER INC.
MERCK & CO., INC.
SANOFI
BAYER AG
GLAXOSMITHKLINE P..
BRISTOL-MYERS SQU..
NOVO NORDISK A/S
ELI LILLY AND CO
ACTAVIS PLC
ABBOTT LABORATORI..
ALLERGAN, INC.
TEVA PHARMACEUTIC..
VALEANT PHARMACEU..
REGENERON PHARMAC..
SHIRE PLC
TAKEDA PHARMACEUT..
ASTELLAS PHARMA I..
Sector Pharmaceuticals
Company contact information
9 Ottiliavej
DK 2500 Valby, Copenhagen
Denmark

Phone : +45 36 30 13 11
Fax : +45 36 30 19 40
Internet : http://www.lundbeck.com
Markets and indexes
- NASDAQ OMX nordic Kopenhagen
- Main Market Large
Stock Exchange Codes
- ISIN Code :  DK0010287234
- Bloomberg Code :  LUN:DC
- Reuters Code :  LUN.CO
- Datastream Code :  DK:LUND
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF